8-K: Precigen Reports Strong PAPZIMEOS Launch, Q3 Net Loss Rises

Precigen, Inc. announced its third quarter 2025 financial results, highlighting the successful commercial launch of PAPZIMEOS for recurrent respiratory papillomatosis and a strengthened cash position despite a significant net loss increase driven by non-cash items.

Summary

• PAPZIMEOS received full FDA approval in August 2025 and is now commercially available and shipping to prescribers in the US for the treatment of adults with RRP.
• The commercial launch of PAPZIMEOS is underway with over 90% of target institutions engaged and more than 100 patients registered in the PAPZIMEOS Patient Hub.
• Private health insurance coverage for PAPZIMEOS has progressed rapidly, covering over 100 million lives, and the therapy is now available through Medicare and Medicaid.
• Long-term follow-up results from the PAPZIMEOS pivotal clinical trial showed ongoing durable complete responses (median 36 months) in 83% of complete responders without additional treatment interventions.
• A Marketing Authorization Application for zopapogene imadenovec for RRP treatment was submitted to the European Medicines Agency in November 2025.
• Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025, which is expected to fund operations to cash flow break-even.
• The company secured a $125 million non-dilutive credit facility in September 2025, receiving the first tranche of $100 million.
• Total revenues increased by $2.0 million in Q3 2025 compared to Q3 2024, primarily due to collaboration and licensing revenue.
• Net loss attributable to common shareholders was $325.3 million, or $(1.06) per basic and diluted share, for Q3 2025, significantly impacted by non-cash items totaling $0.95 per share.

Sentiment

Score: 6

Explanation: While the financial results show a significant increase in net loss due to non-cash accounting items, the operational progress with the PAPZIMEOS launch is exceptionally strong, including FDA approval, rapid market adoption, broad payer coverage, and positive long-term efficacy data. The company's strengthened cash position, expected to fund operations to cash flow break-even, provides a solid foundation. The negative financial metrics are largely non-operational, leading to a moderately positive sentiment overall for the company's strategic direction and product success.

Positives

• Full FDA approval of PAPZIMEOS in August 2025 with a broad label and no requirement for a confirmatory trial, granted ahead of the PDUFA action date.
• Successful commercial launch of PAPZIMEOS, now available and shipping to prescribers in the US as the first and only FDA-approved treatment for adults with RRP.
• Strong early adoption momentum with over 100 patients registered in the PAPZIMEOS Patient Hub and over 90% of target institutions engaged since sales team deployment in September.
• Rapid progress in payer coverage, with more than 100 million private lives covered and availability through Medicare and Medicaid.
• Long-term follow-up data highlighting ongoing durable complete responses (median 36 months) in 83% of complete responders and significant reduction in surgeries (95% in Year 3) after PAPZIMEOS treatment.
• Submission of a Marketing Authorization Application to the European Medicines Agency for PAPZIMEOS, indicating geographic expansion.
• Strong cash, cash equivalents, and investments totaling $123.6 million as of September 30, 2025, expected to fund operations to cash flow break-even.
• Secured a $125 million non-dilutive credit facility in September 2025, with the first $100 million tranche received, strengthening the company's financial foundation.
• Total revenues increased by $2.0 million in Q3 2025 compared to the prior year period, driven by collaboration and licensing revenue.

Negatives

• Net loss attributable to common shareholders significantly increased to $325.3 million, or $(1.06) per basic and diluted share, for Q3 2025, compared to $24.0 million, or $(0.09) per share, for Q3 2024.
• The increased net loss was primarily due to non-cash items, including a $111.5 million increase in the fair value of warrant liabilities and a one-time $179.0 million non-cash deemed dividend on preferred stock.
• Selling, General and Administrative (SG&A) expenses increased by $14.2 million, or 144%, in Q3 2025, mainly due to commercial readiness costs for PAPZIMEOS.
• Research and development expenses increased by $1.0 million, or 9%, in Q3 2025, driven by manufacturing, regulatory filing procedures, and employee-related costs.

Risks

• The company's actual results could differ materially from forward-looking statements due to numerous risks and uncertainties, as detailed in its most recent Annual Report on Form 10-K and subsequent SEC filings.

Future Outlook

The company expects its current cash position of $123.6 million, combined with the $100 million tranche from the credit facility, to fund operations through cash flow break-even. Management is confident in maximizing the impact of the PAPZIMEOS launch, driving ongoing commercialization, and supporting sustainable growth.

Management Comments

• Helen Sabzevari, PhD, President and CEO: "FDA approval of PAPZIMEOS in August marked the beginning of a new era for adults living with RRP... PAPZIMEOS is the first and only treatment for adults with RRP, with an excellent safety profile and unmatched efficacy... We are very encouraged by the strong early interest in PAPZIMEOS and the rapid pace of activation since approval in August and the deployment of our sales force in September."
• Phil Tennant, Chief Commercial Officer: "Patient identification has been outstanding, with prescribers and institutions actively working to bring PAPZIMEOS to their patients... Our team has swiftly mobilized the market: engaging over 90% of target institutions, advancing payer and formulary access, and driving broad educational and promotional outreach. These efforts have laid a firm foundation for PAPZIMEOS as the new standard of care for adults with RRP."
• Harry Thomasian Jr., Chief Financial Officer: "In the third quarter of 2025, we significantly increased investment in commercialization efforts to support the successful launch of PAPZIMEOS... Importantly, based upon our present forecast, we expect our current cash position to fund operations through cash flow break-even, representing a strong financial foundation as we continue to execute on our commercial and strategic objectives."

Industry Context

PAPZIMEOS is positioned as a groundbreaking therapy, being the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). This represents a significant paradigm shift in the management of RRP, a rare and debilitating disease previously addressed primarily through repeated surgeries. By targeting the root cause (HPV 6 or 11 infection), PAPZIMEOS offers a new standard of care for an estimated 27,000 adult RRP patients in the US, potentially reducing the substantial physical, mental, and economic burden associated with the condition.

Comparison to Industry Standards

• PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP.
• It is the first and only approved therapy to address the root cause of RRP (HPV 6 and HPV 11 proteins).
• The PAPZIMEOS pivotal study was the only study in RRP ever conducted with a prospectively defined statistical primary endpoint.
• Dr. Simon R. Best, MD, Associate Professor of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, stated that the durable patient outcomes from the pivotal trial are "nothing short of remarkable," indicating a high standard of efficacy compared to previous symptomatic management.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience a significant increase in net loss per share due to non-cash items, but also benefit from the successful commercial launch of a key product, a strengthened cash position, and the conversion of preferred shares to common.
• Patients (RRP): Gain access to the first and only FDA-approved treatment for RRP, PAPZIMEOS, which addresses the root cause of the disease and offers durable responses, potentially reducing the need for repeated surgeries and improving quality of life.
• Healthcare Providers: Have a new, effective, and safe therapeutic option for adults with RRP, representing a significant advancement in patient care.
• Employees: Benefit from increased investment in commercialization efforts, including sales and marketing, indicating growth and potential for job stability and expansion.
• Creditors: The new $125 million non-dilutive credit facility provides additional financial stability and liquidity.

Next Steps

• Continue rapid commercial launch execution for PAPZIMEOS in the US market.
• Advance payer and formulary access for PAPZIMEOS.
• Drive broad educational and promotional outreach for PAPZIMEOS.
• Pursue European regulatory approval for PAPZIMEOS following the Marketing Authorization Application submission to the EMA.
• Continue Phase 2 clinical trials for PRGN-2009 in HPV-associated cancers, including activating additional clinical sites.

Key Dates

Recommendation

While the operational success of the PAPZIMEOS launch, including FDA approval, strong early adoption, and positive long-term efficacy data, is highly encouraging and represents a significant milestone, the reported Q3 2025 financial results show a substantial increase in net loss. This loss is primarily driven by non-cash items related to warrant liabilities and deemed dividends on preferred stock, which have now been converted. The company's projection to reach cash flow break-even with its current funding is a positive indicator of future financial health. However, until the market sees tangible revenue growth from PAPZIMEOS and a reduction in overall net losses, the stock is best held. Investors should monitor future quarters for evidence of commercial traction translating into improved profitability.

Keywords

Precigen, PGEN, PAPZIMEOS, zopapogene imadenovec-drba, RRP, recurrent respiratory papillomatosis, FDA approval, biopharmaceutical, immunotherapy, AdenoVerse, HPV-associated cancers, PRGN-2009, financial results, Q3 2025, commercial launch, cash flow break-even, credit facility, oncology